Literature DB >> 12052030

Cannabinoid receptors and their ligands.

R G Pertwee1, R A Ross.   

Abstract

There are at least two types of cannabinoid receptors, CB(1) and CB(2), both coupled to G proteins. CB(1) receptors exist primarily on central and peripheral neurons, one of their functions being to modulate neurotransmitter release. CB(2) receptors are present mainly on immune cells. Their roles are proving more difficult to establish but seem to include the modulation of cytokine release. Endogenous agonists for cannabinoid receptors (endocannabinoids) have also been discovered, the most important being arachidonoyl ethanolamide (anandamide), 2-arachidonoyl glycerol and 2-arachidonyl glyceryl ether. Other endocannabinoids and cannabinoid receptor types may also exist. Although anandamide can act through CB(1) and CB(2) receptors, it is also a vanilloid receptor agonist and some of its metabolites may possess yet other important modes of action. The discovery of the system of cannabinoid receptors and endocannabinoids that constitutes the "endocannabinoid system" has prompted the development of CB(1)- and CB(2)-selective agonists and antagonists/inverse agonists. CB(1)/CB(2) agonists are already used clinically, as anti-emetics or to stimulate appetite. Potential therapeutic uses of cannabinoid receptor agonists include the management of multiple sclerosis/spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, vasodilation that accompanies advanced cirrhosis, and cancer. Following their release onto cannabinoid receptors, endocannabinoids are removed from the extracellular space by membrane transport and then degraded by intracellular enzymic hydrolysis. Inhibitors of both these processes have been developed. Such inhibitors have therapeutic potential as animal data suggest that released endocannabinoids mediate reductions both in inflammatory pain and in the spasticity and tremor of multiple sclerosis. So too have CB(1) receptor antagonists, for example for the suppression of appetite and the management of cognitive dysfunction or schizophrenia. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052030     DOI: 10.1054/plef.2001.0341

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  131 in total

1.  Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

4.  Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors:  Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-10       Impact factor: 4.147

5.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 6.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

7.  Is there a role for marijuana in medical practice?

Authors:  Mark A Ware; Meldon Kahan; Anita Srivastava
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

8.  Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Authors:  Alexander F Hoffman; Murat Oz; Ruiqin Yang; Aron H Lichtman; Carl R Lupica
Journal:  Learn Mem       Date:  2007-01-03       Impact factor: 2.460

Review 9.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 10.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.